ETM
EGRX

Euclidean Technologies Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Euclidean Technologies Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-72,263
Closed -$2.11M – 97
2022
Q4 		$2.11M Buy
72,263
+10,000
+16% +$318K 2.01% 18
2022
Q3 		$1.65M Buy
+62,263
New +$2.28M 1.84% 31

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Euclidean Technologies Management's EGRX Position: Q1 2023 in Review

Euclidean Technologies Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 72,263 shares — an estimated $2.11M sold.

Euclidean Technologies Management first reported a position in EGRX in Q3 2022 and held it in 2 quarters. The position peaked at $2.11M in Q4 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • Euclidean Technologies Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Euclidean Technologies Management sold 72,263 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.11M.
  • Euclidean Technologies Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 2 quarters.
  • Euclidean Technologies Management's Eagle Pharmaceuticals, Inc. position peaked at $2.11M in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on Euclidean Technologies Management's 13F filing for Q1 2023, filed 26 Apr 2023.